High Rate of Islets Autoimmunity in Pediatric Patients with Index Admission of Acute Pancreatitis
Table 1
Demographics and clinical characteristics of patients with islet autoantibody positive status.
All islet testing n = 84
Positive for any islet autoantibody titers n = 24 (29%)
All four islet autoantibodies negative n = 60 (71%)
p-value
Age at 1st AP attack (years)
14.0 (8.7–16.3) (1.5–20.4)
14.9 (8.8–17.0) (3.8–19.5)
12.7 (8.7–16.0) (1.5–20.4)
0.36
Sex (female)
45 (54%)
14 (58%)
31 (52%)
0.58
Race White/Caucasian Black/African American Other
75 (89%) 7 (8%) 2 (2%)
19 (79%) 4 (17%) 1 (4%)
56 (93%) 3 (5%) 1 (2%)
0.13
Ethnicity (non-Hispanic/Latino)
81 (96%)
24 (100%)
57 (95%)
0.55
BMI percentile
69.7 (22.5–96.6) n = 79 (0.0–99.8)
56.6 (15.8–91.8) n = 21 (0.0–99.3)
73.0 (24.0–97.1) n = 58 (0.0–99.8)
0.37
BMI ≥ 85th percentile
31/79 (39%)
6/21 (29%)
25/58 (43%)
0.24
SAP during AP episode
16 (19%)
3 (13%)
13 (22%)
0.54
Comorbid conditions
49/83 (59%)
13 (54%)
36/59 (61%)
0.57
Exocrine insufficiency at 1st attack
0/80 (0%)
0/23 (0%)
0/57 (0%)
1.00
Insulin use prior to AP
0 (0%)
0 (0%)
0 (0%)
1.00
Pre-DM/DM any point up to 12 months post AP
19/71 (27%)
0/16 (0%)
19/55 (35%)
0.04
Low C-peptide up to 12 months post AP (<0.73 ng/mL)
5/30 (17%)
0/3 (0%)
5/27 (19%)
1.00
Time AP to abnormal C-peptide (years) up to 12 months post AP
1.0 (0.6–1.0) n = 5
–
1.0 (0.6–1.0) n = 5
–
C-peptide 3 months (ng/mL)
1.4 (1.1–2.0) n = 20
1.5 (1.3–1.7) n = 2
1.4 (1.0–2.1) n = 18
1.00
C-peptide 12 months (ng/mL)
1.9 (0.9–2.9) n = 21
2.2 (1.2–3.3) n = 2
1.9 (0.7–2.9) n = 19
0.59
Data presented as median (25th–75th percentile) (min–max) or n (%). p-values for testing positive versus negative groups. Variables with missing data are noted with “n = ” or “/n” (denominator indicating how many had data) if not noted then full data were available. AP, acute pancreatitis; BMI, body mass index; SAP, severe acute pancreatitis; DM, diabetes mellitus. Bold values denote the statistical significance p-value.
